Case Type: Mergers & Acquisitions

ProAssurance Corporation (NYSE: PRA), relating to the proposed merger with The Doctors Company. Under the terms of the agreement, ProAssurance stockholders will receive $25.00 per share in cash.

Radius Recycling, Inc. (NASDAQ: RDUS), relating to the proposed merger with Toyota Tsusho America, Inc. Under the terms of the agreement, Toyota Tsusho will acquire all shares of Radius, with Radius shareholders receiving $30.00 per share in cash.

Endo, Inc. (OTC: NDOI), relating to the proposed merger with Mallinckrodt plc. Under the terms of the agreement, Endo shareholders will own 49.9% of the combined company on a pro forma basis.

2seventy bio, Inc. (NASDAQ: TSVT), relating to the proposed merger with Bristol Myers Squibb. Under the terms of the agreement, Bristol Myers Squibb will acquire 2seventy bio, with 2seventy shareholders receiving $5.00 per share in cash.

Avalon GloboCare Corp. (NASDAQ: ALBT), relating to the proposed merger with YOOV Group Holding Limited. Under the terms of the agreement, Avalon equity holders are expected to own between approximately 2.5% to 2.2% of the common stock of the combined company.

Checkpoint Therapeutics, Inc. (NASDAQ: CKPT), relating to the proposed merger with Sun Pharmaceutical Industries Limited. Under the terms of the agreement, Checkpoint stockholders will receive, for each share of common stock they hold, a cash payment of $4.10, and a non-transferable contingent value right entitling the stockholder to receive up to $0.70 in cash.

Redfin Corporation (NASDAQ: RDFN), relating to the proposed merger with Rocket Companies. Under the terms of the agreement, Redfin shares will be converted into the right to receive 0.7926 shares of Rocket’s Class A common stock.

Blackboxstocks Inc. (NASDAQ: BLBX), relating to the proposed merger with REalloys Inc. Under the terms of the agreement, it is anticipated Blackbox’s stockholders will own approximately 7.3% of the combined company’s common stock.

Walgreens Boots Alliance, Inc. (NASDAQ: WBA), relating to the proposed merger with Sycamore Partners. Under the terms of the agreement, WBA shareholders will receive $11.45, and one non-transferable right to receive up to $3.00, in cash, per WBA share.

Chimerix, Inc. (NASDAQ: CMRX), relating to the proposed merger with Jazz Pharmaceuticals. Under the terms of the agreement, Chimerix shareholders will receive $8.55 per share.